基于磁共振成像的前列腺癌预测新模型的外部验证
该研究在307例接受mpMRI后经会阴超声融合活检的男性中外部验证了三种结合mpMRI与临床变量的前列腺癌风险模型。结果显示MRI-ERSPC-3/4、ModRad和ModDis的AUC分别为0.82、0.85和0.83,校准曲线显示MRI-ERSPC-3和-4的截距最佳,净获益分析表明MRI-ERSPC-3/4模型优于其他两种模型,尤其在风险阈值≤15%时具有鉴别优势,可能有助于减少不必要的活检。
要点
- MRI-ERSPC-3/4模型在外部验证中AUC为0.82,校准和净获益优于ModRad和ModDis模型。
- 在临床显著前列腺癌风险阈值≤15%时,MRI-ERSPC-3/4模型较其他模型显示出鉴别优势。
- 结合mpMRI的风险模型可能帮助减少不必要的前列腺活检。
核心结论
- MRI-ERSPC-3/4风险模型在外部验证中表现出良好的预测性能,可能有助于减少不必要的前列腺活检。
研究设计与样本
- mpMRI按PI-RADS v2.0评分,临床显著前列腺癌定义为ISUP分级分组≥2。
- 比较三种模型(MRI-ERSPC-3/4、ModRad和ModDis)的预测性能,使用ROC曲线分析(AUC)、校准曲线和决策曲线评估净获益。
主要发现
- MRI-ERSPC-3/4、ModRad和ModDis的AUC分别为0.82、0.85和0.83。
- 校准曲线分析显示MRI-ERSPC-3和-4的截距最佳,分别为0.35和0.76。
- 净获益分析表明MRI-ERSPC-3/4风险模型较其他两种验证模型有明显益处。
- MRI-ERSPC-3/4风险模型在临床显著前列腺癌风险阈值≤15%时较其他风险模型显示出鉴别优势。
关键数值与推荐
- 临床显著前列腺癌定义为ISUP分级分组≥2。
- mpMRI按PI-RADS v2.0评分。
- MRI-ERSPC-3/4、ModRad和ModDis的AUC分别为0.82、0.85和0.83。
- MRI-ERSPC-3和-4的校准截距分别为0.35和0.76。
- MRI-ERSPC-3/4模型在风险阈值≤15%时显示鉴别优势。
临床怎么用
- 在临床实践中,对于接受mpMRI的前列腺癌疑似患者,可使用MRI-ERSPC-3/4风险模型辅助决策,可能减少不必要的活检。
局限性
- 回顾性研究设计。
- 样本量307例,来自两家德国中心。
- 外部验证队列的局限性需进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To validate, in an external cohort, three novel risk models, including the recently updated European Randomized Study of Screening for Prostate Cancer (ERSPC) risk calculator, that combine multiparametric magnetic resonance imaging (mpMRI) and clinical variables to predict clinically significant prostate cancer (PCa). PATIENTS AND METHODS: We retrospectively analysed 307 men who underwent mpMRI prior to transperineal ultrasound fusion biopsy between October 2015 and July 2018 at two German centres. mpMRI was rated by Prostate Imaging Reporting and Data System (PI-RADS) v2.0 and clinically significant PCa was defined as International Society of Urological Pathology Gleason grade group ≥2. The prediction performance of the three models (MRI-ERSPC-3/4, and two risk models published by Radtke et al. and Distler et al., ModRad and ModDis) were compared using receiver-operating characteristic (ROC) curve analyses, with area under the ROC curve (AUC), calibration curve analyses and decision curves used to assess net benefit. RESULTS: The AUCs of the three novel models (MRI-ERSPC-3/4, ModRad and ModDis) were 0.82, 0.85 and 0.83, respectively. Calibration curve analyses showed the best intercept for MRI-ERSPC-3 and -4 of 0.35 and 0.76. Net benefit analyses indicated clear benefit of the MRI-ERSPC-3/4 risk models compared with the other two validated models. The MRI-ERSPC-3/4 risk models demonstrated a discrimination benefit for a risk threshold of up to 15% for clinically significant PCa as compared to the other risk models. CONCLUSION: In our external validation of three novel prostate cancer risk models, which incorporate mpMRI findings, a head-to-head comparison indicated that the MRI-ERSPC-3/4 risk model in particular could help to reduce unnecessary biopsies.
引用
- Püllen L, Radtke JP, Wiesenfarth M, et al. External validation of novel magnetic resonance imaging-based models for prostate cancer prediction. BJU Int. 2019. PMID: 31758738. doi:10.1111/bju.14958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。